Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SmofKabiven Peripheral vs Compounded Emulsion in Adult Surgical Patients
NCT03792087Phase 3Completed
- Sponsor
- Fresenius Kabi
- Start
- Dec 2017
- Primary completion
- Dec 2018
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of SmofKabiven Peripheral in Nutritional deficiency, sponsored by Fresenius Kabi. Primary endpoint: Serum Prealbumin at 6 days. Started Dec 2017; status: completed.
02
Drugs
SmofKabiven Peripheral
03
Conditions
Nutritional deficiency
Beyond the preview
Go deeper on NCT03792087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03792087.